2024-520328-27-00招募中2 期
J1R-MC-GZFD: A Parallel-Group Treatment, Phase 2, Double-Blind study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants with Type 2 Diabetes Mellitus on a Stable Dose of Semaglutide or Tirzepatide who Failed to Achieve HbA1c Goal
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 14
- 主要终点
- Change from Baseline in Hemoglobin A1c (HbA1c) [Time Frame: Baseline, Week 24]
研究概览
简要总结
To compare HbA1c lowering efficacy of LY3457263 versus placebo at 24 weeks
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Have type 2 diabetes
- •Have overweight or obesity
- •Have a stable body weight for three months prior to screening
- •Be on a stable dose of injectable semaglutide or injectable tirzepatide for at least three months
排除标准
- •Have type 1 diabetes
- •Have taken any medications or alternative remedies for weight loss within three months prior to screening
结局指标
主要结局
Change from Baseline in Hemoglobin A1c (HbA1c) [Time Frame: Baseline, Week 24]
Change from Baseline in Hemoglobin A1c (HbA1c) [Time Frame: Baseline, Week 24]
次要结局
未报告次要终点
研究者
Lilly Clinical Trials information desk
Scientific
Eli Lilly & Co.
研究点 (14)
Loading locations...
相似试验
招募中
2 期
Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative ColitisUlcerative Colitis2023-504673-20-00Janssen - Cilag International102
招募中
1 期
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid ArthritisNCT07258849Eli Lilly and Company141
招募中
2 期
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT07266441Janssen Research & Development, LLC157
招募中
1 期
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D MutationNCT07259590Genfleet Therapeutics (Shanghai) Inc.126
招募中
2 期
A Phase 2 Randomized Trial Evaluating Efficacy of AGA2118 in Postmenopausal Women with Low Bone Mass (ARTEMIS)Postmenopausal Osteoporosis2024-515610-41-00Angitia Inc. Ltd.260